Viatris Inc.
VTRS
Classifica tra le azioni
#1102
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Prezzo delle azioni
$18.50
Capitalizzazione di mercato
$21.25B
Variazione (1 giorno)
1.32%
Variazione (1 anno)
79.45%
Paese
US
Scambia Viatris Inc. (VTRS)
Categoria
Healthcare
Rapporto P/E per Viatris Inc. (VTRS)
Rapporto P/E al October 2026 TTM: -48.44
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Viatris Inc., il rapporto P/E attuale (TTM) è -48.44. Alla fine del 2023, il rapporto P/E era 237.65.
Storico del rapporto P/E per Viatris Inc. da 2004 a 2026
Rapporto P/E alla fine di ogni anno
| Anno | Rapporto P/E | Cambia |
|---|---|---|
| 2026 (TTM) | -48.44 | 106.76% |
| 2024 | -23.43 | -109.86% |
| 2023 | 237.65 | 3,561.56% |
| 2022 | 6.49 | -150.36% |
| 2021 | -12.89 | -23.37% |
| 2020 | -16.82 | -102.51% |
| 2019 | 670.00 | 1,568.83% |
| 2018 | 40.15 | 23.36% |
| 2017 | 32.55 | -21.33% |
| 2016 | 41.37 | 30.38% |
| 2015 | 31.73 | 31.72% |
| 2014 | 24.09 | -12.25% |
| 2013 | 27.45 | 54.35% |
| 2012 | 17.79 | 3.26% |
| 2011 | 17.22 | -13.30% |
| 2010 | 19.86 | -17.85% |
| 2009 | 24.18 | -257.52% |
| 2008 | -15.35 | 544.28% |
| 2007 | -2.38 | -108.19% |
| 2006 | 29.09 | 24.24% |
| 2005 | 23.41 | 28.15% |
| 2004 | 18.27 | 0.00% |
Rapporto P/E per aziende simili o concorrenti
| Azienda | P/E Ratio | Differenza del P/E Ratio | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -172.16% |
IN
|
Come leggere un P/E ratio?
Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.
Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.
Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.